Columvi improves OS in R/R DLBCL in phase III trial – The Cancer Letter
Genentech’s phase III STARGLO study met its primary endpoint of overall survival. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.Login […]